Genetic Engineering & Synthetic Biology Ethics Policy

1. Preamble and Ethical Foundation

Helix BioMedical approaches genetic engineering and synthetic biology from a position grounded in the conviction that scientific capability carries moral weight. The tools of modern molecular biology -- particularly CRISPR/Cas9 gene editing and the broader field of synthetic biology -- represent some of the most consequential technologies in human history. Their potential to alleviate suffering, eliminate inherited disease, restore ecological balance, and expand the frontiers of human knowledge is matched only by their potential for misuse, unintended harm, and the erosion of boundaries that protect human dignity, biodiversity, and the integrity of biological systems.

This Ethics Policy reflects Helix BioMedical's faith-based understanding that the capacity to edit the code of life is not a license to do so without constraint, humility, or accountability to something larger than individual curiosity or commercial interest. We believe that responsible science is not slow science or timid science -- it is science conducted with clear awareness of context, consequence, and the communities affected by research decisions. This policy establishes the ethical standards that govern all research, education, and application of genetic engineering and synthetic biology within Helix BioMedical's programs, platforms, and partnerships.

This policy is binding on all Helix BioMedical personnel -- including employees, contractors, volunteers, and affiliated researchers -- and on all students and research participants who engage with genetic engineering or synthetic biology tools, materials, or computational resources through Helix BioMedical. Violations of this policy may result in removal from programs, termination of research access, reporting to relevant regulatory authorities, and other consequences described in Section 12 of this document.

2. Ethical Framework for CRISPR/Cas9 Research

Helix BioMedical's approach to CRISPR/Cas9 research is guided by four core ethical principles: beneficence (the work should produce genuine benefit), non-maleficence (the work should not cause harm, particularly irreversible harm), justice (the benefits and risks of research should be distributed equitably and not exploited from vulnerable populations), and respect for autonomy (individuals affected by genetic modifications have a right to informed participation in decisions that affect them). These principles are drawn from established bioethical tradition and adapted to the specific challenges posed by gene editing technology.

In practice, applying these principles to CRISPR/Cas9 research means that all research projects conducted through Helix BioMedical must have a clearly articulable benefit case. Research conducted purely for technical novelty, without meaningful potential benefit, or primarily to demonstrate capability rather than serve a health or scientific goal, falls outside the scope of what Helix BioMedical supports. Research that involves editing the genomes of organisms in ways that could have unpredictable ecosystem effects requires heightened justification and additional oversight as described in Section 6.

Gene drive research -- the development of heritable genetic modifications designed to spread through wild populations -- is prohibited under this policy without explicit written authorization from Helix BioMedical's Ethics Review Committee and compliance with all applicable federal and international regulatory requirements. The potential for gene drives to cause irreversible ecological change demands a level of institutional capacity and regulatory oversight that exceeds the scope of community-based research programs at our current stage of development.

Research involving human embryos, human germline editing, or the creation of heritable genetic modifications in human beings is prohibited under this policy, consistent with the 2015 International Summit on Human Gene Editing consensus, the 2019 recommendations of the International Commission on the Clinical Use of Human Germline Genome Editing, and the current state of international scientific and ethical consensus on this subject. Helix BioMedical does not conduct and will not facilitate human germline editing research.

3. Responsible Use of Gene Editing Technology

Responsible use of CRISPR/Cas9 and related gene editing tools begins with ensuring that researchers -- including students -- have adequate theoretical preparation and supervised practical training before conducting independent experiments. Helix BioMedical requires all participants in hands-on gene editing work to complete foundational training in CRISPR biology, off-target effect assessment, delivery mechanism selection, and result interpretation before progressing to independent laboratory work. Competency assessments are conducted at each stage of training progression.

All experimental protocols involving gene editing must be reviewed and approved by a designated faculty supervisor before work begins. Protocols are evaluated for scientific rationale, risk assessment, containment requirements, and alignment with this Ethics Policy. Unapproved protocols may not proceed regardless of the researcher's level of experience or the apparent simplicity of the proposed work. This requirement exists not to obstruct research but to ensure that a qualified second perspective is applied to every experimental design before biological materials are committed.

Researchers are expected to use the minimal effective dose of gene editing reagents, the most specific guide RNA designs achievable for a given application, and the most contained experimental format that permits the scientific objective to be met. This principle of proportionality -- using the least invasive approach consistent with scientific objectives -- reflects both ethical responsibility and practical good science, since off-target effects and unintended genomic disruptions are most effectively minimized through careful reagent design and minimal-intervention approaches.

Results of gene editing experiments, including off-target analysis data, must be documented completely and accurately. Selective reporting of results, omission of negative findings, or modification of data to improve the apparent specificity or efficiency of a gene editing approach constitutes scientific misconduct and will be treated as such under this policy regardless of the researcher's intent.

4. Dual-Use Research Concerns

Dual-use research of concern (DURC) is life sciences research that, based on current understanding, could be directly misapplied to pose a significant threat to public health, safety, security, national security, or the safety and security of the international community. CRISPR/Cas9 technology has recognized dual-use potential because the same tools used to develop therapies for genetic disease can theoretically be applied to engineer biological agents capable of causing harm.

Helix BioMedical explicitly prohibits any research that -- regardless of stated intent -- could plausibly increase the transmissibility, pathogenicity, immune evasion capacity, or antibiotic resistance of any pathogen; engineer novel toxic or harmful compounds; reconstruct or reconstitute any eradicated pathogen; alter host range or infectivity of any virus, bacterium, or parasite; or otherwise create biological agents with enhanced capacity to cause harm to human, animal, or plant populations. This prohibition is absolute and admits no exceptions, regardless of the scientific rationale offered.

All research proposals submitted to Helix BioMedical are screened against DURC criteria by program faculty before approval. Proposals that raise DURC concerns are escalated to the Ethics Review Committee for a formal determination. In cases of ambiguity, Helix BioMedical will consult with external biosecurity experts and, where required by law, the Institutional Biosafety Committee structure described in Section 5 of this policy.

Researchers who become aware of information suggesting that their work -- or work conducted by others at Helix BioMedical -- has dual-use implications not identified during initial review are obligated to immediately report this concern to program faculty or the Ethics Review Committee. Helix BioMedical maintains a confidential reporting channel for such concerns at [email protected] with the subject line "DURC Concern -- Confidential." Good-faith reports of potential dual-use concerns will never be used as grounds for adverse action against the reporting individual.

5. Biosafety and Biosecurity

Helix BioMedical conducts biological research activities in accordance with the biosafety levels defined by the U.S. Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in their "Biosafety in Microbiological and Biomedical Laboratories" (BMBL) guidelines. Current Helix BioMedical research activities are designed to operate at Biosafety Level 1 (BSL-1) and Biosafety Level 2 (BSL-2). Work requiring BSL-3 or BSL-4 containment is not conducted at Helix BioMedical facilities and is not supported through the organization's programs.

All laboratory facilities used by Helix BioMedical are designed, equipped, and maintained in compliance with the physical containment requirements appropriate to the biosafety level at which work is conducted. Personal protective equipment (PPE) requirements are posted at all laboratory entry points and are mandatory for all personnel and students present during biological work. Compliance with PPE requirements is monitored by laboratory supervisors and violations are subject to immediate removal from the laboratory and disciplinary review.

Biosecurity measures -- the protection of biological materials from theft, misuse, or unauthorized access -- are distinct from biosafety but equally important. All biological materials used in Helix BioMedical research, including plasmids, cell lines, viral vectors, recombinant proteins, and CRISPR reagents, are inventoried, labeled, and stored in secured facilities accessible only to authorized personnel. Transfer of biological materials from Helix BioMedical premises requires prior written authorization from the program director and must comply with all applicable U.S. Department of Transportation, CDC, and USDA transfer regulations.

Incidents involving potential biosafety breaches -- including spills, exposures, equipment failures, loss of materials, or observations of unauthorized access to biological materials -- must be reported immediately to the laboratory supervisor and documented in the incident log. Serious incidents may require notification of regulatory authorities and will trigger a formal review process to prevent recurrence.

6. Environmental Considerations

Research involving genetically modified organisms (GMOs) -- including bacteria, yeast, plant cells, and animal cell lines -- carries the potential for environmental impact if modified organisms or their genetic material is released into the environment. Helix BioMedical's research programs are designed to operate under strict containment to prevent any unintended environmental release. All research involving GMOs must be conducted within approved containment facilities, and all GMO waste must be decontaminated through autoclave sterilization or chemical inactivation before disposal in accordance with applicable local and federal waste management regulations.

Research that involves whole-organism gene editing in plant or animal systems with any potential pathway to environmental exposure requires an Environmental Risk Assessment (ERA) prior to initiation. The ERA must identify the proposed organism, the nature of the genetic modification, the intended research purpose, the containment measures in place, and a systematic analysis of potential environmental consequences if containment were to fail. ERAs are reviewed by the Ethics Review Committee and approved, modified, or rejected before work begins.

Helix BioMedical recognizes that its faith-based mission includes a stewardship obligation to the natural environment. This means that even where environmental releases might be technically permissible under existing regulations, the organization applies a precautionary approach to research involving organisms or modifications with potential for ecological disruption. We believe that the burden of proof lies with researchers to demonstrate that proposed environmental interventions are safe, reversible, and proportionate to the benefit sought -- not with regulators or communities to prove that harm will occur.

7. Human Subjects Protections

Any research involving human subjects -- including collection of biological specimens, analysis of personally identifiable health data, administration of experimental interventions, or enrollment of individuals in research protocols -- must comply with the Federal Policy for the Protection of Human Subjects (the "Common Rule," 45 CFR Part 46), the Declaration of Helsinki, and all applicable state law governing research with human participants. Helix BioMedical does not operate an Institutional Review Board (IRB) directly; research involving human subjects that meets the threshold for IRB review must be reviewed by an external IRB before commencing.

Informed consent is a foundational requirement for all research involving human participants. Informed consent processes must be documented, must be conducted in a language and format accessible to the participant, must be free from coercion or undue influence, and must disclose the nature and purpose of the research, the foreseeable risks and benefits, the voluntary nature of participation, the right to withdraw without penalty, and how participant data and specimens will be used, stored, and protected. Helix BioMedical maintains model consent document templates that faculty must review and adapt before initiating any human subjects research.

Research involving somatic gene editing in human subjects -- that is, genetic modifications to non-reproductive cells intended to treat or prevent disease in individual patients -- must comply with current FDA regulations governing gene therapy, including IND (Investigational New Drug) application requirements where applicable. Helix BioMedical does not currently conduct gene therapy research in human subjects. Any future plans to do so would require regulatory authorization, IRB oversight, and a formal amendment to this Ethics Policy.

Data collected from human subjects in connection with Helix BioMedical research is treated as protected health information where applicable under HIPAA and is subject to the organization's Privacy Policy and HIPAA Notice of Privacy Practices. De-identified datasets generated from human subjects research may be shared with the research community in accordance with the data sharing principles described in Section 8, provided that de-identification is conducted in compliance with HIPAA Safe Harbor or Expert Determination standards.

8. Data Sharing and Open Science Principles

Helix BioMedical is committed to the principles of open science: that scientific knowledge generated with community resources should be made available to the broader scientific community in a timely, accessible, and reproducible manner. This commitment reflects both practical scientific values -- open data accelerates discovery and allows independent verification of results -- and our faith-based conviction that knowledge generated in service of human health should not be locked behind paywalls or proprietary restrictions that serve commercial interests at the expense of public benefit.

Research data generated through Helix BioMedical programs will be deposited in appropriate public repositories where feasible and consistent with applicable privacy requirements, intellectual property considerations, and biosecurity concerns. Genomic sequence data will be submitted to NCBI GenBank or equivalent repositories. Protein structure data will be submitted to the Protein Data Bank (PDB). Research code and computational workflows will be made available through public version control platforms such as GitHub under open-source licenses where appropriate.

Open science commitments are balanced against legitimate constraints. Data sharing that would compromise patient privacy, that involves dual-use research of concern, that involves proprietary third-party information, or that is subject to export control regulations may be restricted or delayed. Students and researchers who generate data through Helix BioMedical programs may negotiate data sharing arrangements as part of their intellectual property agreements with the organization, as described in the Intellectual Property Policy at /legal/intellectual-property.

Helix BioMedical supports pre-registration of research protocols, inclusion of negative results in internal technical reports, and citation of data sources in all research communications. We discourage publication bias -- the selective reporting of only positive or novel results -- as inconsistent with rigorous science and potentially harmful when other researchers rely on published data to inform their own research decisions.

9. NIH Guidelines Compliance

Helix BioMedical conducts research with recombinant and synthetic nucleic acid molecules in accordance with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines). Although the NIH Guidelines formally apply to research funded by NIH, Helix BioMedical adopts these guidelines as the minimum standard for all recombinant DNA research regardless of funding source, because they represent the most widely accepted and scientifically grounded framework for conducting this type of research responsibly.

In particular, Helix BioMedical adheres to the NIH Guidelines' provisions regarding: the classification of experiments according to biosafety risk category; the prohibition on experiments involving deliberate release of recombinant organisms into the environment without prior regulatory approval; the prohibition on major actions involving recombinant DNA in human subjects without prior NIH/OBA review; the requirement for institutional biosafety oversight through a committee function that evaluates research protocols; and the obligation to report any significant problems, violations, or deviations from the guidelines to appropriate authorities.

Helix BioMedical maintains a Biosafety Committee function that is responsible for reviewing research protocols, maintaining records of approved research activities, ensuring that laboratory safety training is current and documented, overseeing the use and disposal of recombinant materials, and reviewing any incidents or potential violations for corrective action. The Biosafety Committee reports to the organization's leadership and convenes at least quarterly or as needed when new research proposals require review.

Research conducted by students through Helix BioMedical's programs that involves recombinant or synthetic nucleic acid molecules requires explicit Biosafety Committee approval before beginning. Students are responsible for submitting research proposals in the format required by the committee and for cooperating with any requests for additional information or protocol modifications requested during the review process.

10. International Biosafety Protocols

Helix BioMedical recognizes that genetic engineering and synthetic biology operate within a framework of international agreements and scientific norms that transcend national boundaries. The organization aligns its practices with the Cartagena Protocol on Biosafety, an international treaty under the Convention on Biological Diversity that governs the transfer, handling, and use of living modified organisms (LMOs). Although the United States is not a party to the Cartagena Protocol, Helix BioMedical adopts its risk assessment framework as a standard of international best practice.

The Sendai Framework provisions relevant to biological risks, the Biological Weapons Convention (BWC) prohibitions on the development, production, and stockpiling of biological weapons and toxins, and the Tianjin Biosecurity Guidelines for Codes of Conduct for Scientists are incorporated into Helix BioMedical's operational standards. The Tianjin Guidelines in particular -- developed through a joint U.S.-China workshop and widely adopted by international scientific organizations -- provide a practical code of conduct that addresses researcher responsibility for biosecurity in a manner directly applicable to our programs.

Transfer of biological materials, research protocols, or genetic information outside of the United States must comply with U.S. export control laws, including regulations administered by the Bureau of Industry and Security (BIS) under the Export Administration Regulations (EAR) and, where applicable, the International Traffic in Arms Regulations (ITAR). Researchers considering international collaborations or data transfers involving genetic material or related technology must consult with Helix BioMedical administration before proceeding to ensure compliance with applicable export control requirements.

11. Student Ethical Obligations

Students enrolled in Helix BioMedical programs who engage with gene editing tools, synthetic biology materials, or computational research infrastructure assume specific ethical obligations that are conditions of their continued participation. These obligations supplement and do not replace the academic integrity and safety requirements described in the Non-Accredited Education Disclosure and the general Terms of Service.

Students are obligated to: conduct all gene editing and synthetic biology work only within Helix BioMedical supervised laboratory environments unless explicitly authorized in writing to do otherwise; refrain from removing biological materials, recombinant constructs, plasmids, viral vectors, or cell lines from the laboratory without written authorization from a faculty supervisor; report any observations of unsafe, potentially harmful, or ethically concerning practices by other students or personnel immediately to program administration; complete all required ethics training modules and biosafety training before accessing laboratory resources; and apply the dual-use research screening principles described in Section 4 to their own research ideas before submitting proposals.

Students who engage with Helix BioMedical's computational protein engineering pipeline have additional obligations specific to the digital research environment: they must not attempt to use computational tools to design biological agents with the potential for harm, must not attempt to access or exfiltrate model weights, training data, or proprietary pipeline components beyond what is required for their research work, and must immediately report any computational outputs that appear to describe potentially dangerous biological configurations, even if the research objective was entirely benign.

Students who complete Helix BioMedical programs carry the organization's reputation into whatever contexts they apply their knowledge. We ask -- and contractually require -- that alumni of our programs represent their training accurately, apply their knowledge responsibly, and uphold the ethical standards embodied in this policy in their professional and independent research activities. Conduct by alumni that brings disrepute to Helix BioMedical or that involves the misuse of knowledge gained through our programs may result in revocation of completion credentials and referral to appropriate regulatory or law enforcement authorities.

12. Governance, Review, and Accountability

This Ethics Policy is maintained by Helix BioMedical's Ethics Review Committee, a standing committee that includes organizational leadership, program faculty, and at least one external advisor with expertise in bioethics, biosafety, or science policy. The committee is responsible for reviewing this policy at least annually, updating it in response to significant changes in the scientific, regulatory, or ethical landscape, and adjudicating alleged violations of the policy's provisions.

Alleged violations of this Ethics Policy may be reported confidentially to [email protected] with the subject line "Ethics Policy Concern -- Confidential." Reports will be reviewed by the Ethics Review Committee within ten (10) business days. The committee has authority to conduct investigations, interview relevant parties, review research records, and recommend actions up to and including suspension of research activities, removal from programs, termination of employment or contractor relationships, and referral to external authorities.

Individuals who are the subject of an ethics investigation retain the right to be informed of the nature of the allegation (subject to confidentiality protections for reporters), to provide a written response to the committee's inquiry, and to appeal a committee determination to organizational leadership. This process is designed to be fair, thorough, and proportionate to the seriousness of the conduct at issue.

Helix BioMedical views ethics not as a constraint on scientific ambition but as the foundation on which trustworthy science is built. We recognize that this policy cannot anticipate every ethical question that will arise as gene editing and synthetic biology continue to evolve at a rapid pace. We commit to engaging seriously with ethical questions as they emerge, updating our policies in a timely manner, and fostering a culture in which ethical concern is valued, not treated as an obstacle. Questions and comments about this policy are welcome at [email protected] or by calling (702) 825-0288.